Phase II clinical study examining CTT's Calmare pain therapy medical device completed

NewsGuard 100/100 Score

Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that Thomas J. Smith, MD FACP, and co-investigator Patrick J. Coyne, MSN, APRN, FAAN, of Virginia Commonwealth University's Massey Cancer Center have completed their open Phase II clinical study examining CTT's Calmare® pain therapy medical device's efficacy treating patients suffering with severe pain from chemotherapy induced peripheral neuropathy (CIPN). Dr. Smith is Endowed Professor for Palliative Care Research and Medical Director for the Thomas Palliative Care Unit at Massey Cancer Center, and Patrick Coyne is Clinical Director of the Thomas Palliative Care Services at Massey Cancer Center.  

Dr. Smith, an international leader in palliative care and pain management, has detailed the results of this clinical study in an article which has undergone professional peer review. This peer-reviewed study has been accepted for publication in a highly respected medical journal. Details on the specific journal and the publication date are expected to be released in a few weeks.

CTT's personnel trained Dr. Smith's clinical staff in the use of the Calmare® pain therapy medical device, a non-invasive treatment for chronic and cancer pain neuropathies no longer treatable because of a failed drug therapy program. The Phase II study began in early June 2009 and the last patients received the standard 10-day treatment protocol with the Calmare pain therapy medical device in late November 2009.  

The study examined the device's effect on pain associated with CIPN that can produce sharp pains in the hands and feet of cancer patients who are undergoing chemotherapy. This debilitating pain affects about 30 to 40 percent of cancer patients treated with chemotherapy and typically develops into a classic stocking-and-glove pain that can last for many years. "Exploring ways to treat pain other than prescribing opioids such as morphine is key to our mission of improving the quality of life for cancer patients," said Dr. Smith.

"I have had the honor and pleasure of working with Dr. Smith and Patrick Coyne for about one year and I greatly appreciate their expertise and dedication to improving palliative care for patients, said Aris Despo, CTT's Executive VP, Business Development. "This experience has been very rewarding to me professionally and personally because of the pain relief we offer to patients."

The non-invasive Calmare pain therapy medical device, which uses the biophysical "Scrambler Therapy" technology developed in Italy by CTT's client, Professor Giuseppe Marineo, was brought to CTT through the efforts of the Zangani Investor Community™ and with the cooperation of Mr. Giuseppe Belcastro, legal counsel for Professor Marineo. The device has US FDA 510(k) clearance and European Union CE certification, which opened the doors to CTT's current international distribution agreements covering nearly half of the world's population.

SOURCE Competitive Technologies, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Examining how pain could play a direct protective role in the gut